Recombinant human thrombopoietin safety and efficacy in pediatric allogeneic hematopoietic stem cell transplantation: A cohort study

Table 4 Bleeding for hematologic diseases patients after recombinant human thrombopoietin treatment in different age groups, n (%)

Variables	Total (n = 79)	0- to 9-year-old group (n = 36)	10- to 17-year-old group (n = 43)	P value
Bleeding	16 (20.3)	7 (19.4)	9 (20.9)	0.870
Bleeding sites				0.891
Gastrointestinal tract	10 (12.7)	5 (13.9)	5 (11.6)
Bladder	3 (3.8)	1 (2. 8)	2 (4.7)
Mucosal and skin	1 (1.3)	0	1 (2.3)
Multiple sites	2 (2.5)	1 (2. 8)	1 (2.3)

rhTPO: Recombinant human thrombopoietin.